転移性サルコマトイド性腎臓細胞癌における多分野治療による長期生存率:症例報告と文献レビュー

Xin Li1, Weijia Wang2, Lingjun Meng1

  • 1Department of Radiotherapy, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, China.

Frontiers in oncology
|September 3, 2025
PubMed
まとめ

サルコマトイド腎臓細胞癌 (SRCC) は攻撃的ですが,併用療法と多分野治療で完全な寛解を達成した患者がいます. このケースは,転移性SRCCの2.5年を超える稀な長期生存率を強調しています.

関連する概念動画

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
448
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K